Florbetapir F 18

Drug Profile

Florbetapir F 18

Alternative Names: 18F-AV-45; Amyloid imaging agent; Amyvid; AV-45; Florbetapir (18F); Florpiramine F 18

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Pennsylvania
  • Developer Avid Radiopharmaceuticals
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease
  • No development reported Parkinson's disease

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 26 Nov 2015 Wolfson Foundation and University College London plan a clinical trial for Alzheimer's disease (Diagnosis) in United Kingdom (IV) (UKCRN19997)
  • 23 Jul 2015 Final efficacy and adverse events data from a phase III trial in Alzheimer's disease released by Avid Radiopharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top